Kazuo Fujihara, MD, PhD, Fukushima Medical University School of Medicine, Fukushima, Japan, gives an overview of novel treatment strategies for aquaporin-4 immunoglobulin G antibodies (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD), which notably include cell therapies such as hematopoietic stem cell transplantation (HSCT), chimeric antigen receptor (CAR)-T-cell therapy, and more recently, induction of tolerance using engineered dendritic cells (DCs). This interview took place during the XXV World Congress of Neurology.